EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 540 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR TRACERx EVO, a new programme to transform lung cancer research November 9, 2022 Learning From Being Lost July 14, 2021 Take a Small Step April 21, 2021 Doctors Think Woman Has A Brain Tumor, But Then They Open... June 17, 2019 Load more HOT NEWS Breast Cancer Risk Genes Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL The Caregiver Curve
